相似文献
1
Importance of low diagnostic Accuracy for early Parkinson's disease.
Mov Disord. 2018 Oct;33(10):1551-1554. doi: 10.1002/mds.27485. Epub 2018 Oct 4.
2
How valid is the clinical diagnosis of Parkinson's disease in the community?
J Neurol Neurosurg Psychiatry. 2003 Jul;74(7):1005-6. doi: 10.1136/jnnp.74.7.1005.
3
Accuracy of the Early Diagnosis of Parkinson's Disease.
Mov Disord. 2023 Aug;38(8):1573-1574. doi: 10.1002/mds.29556.
4
Variability in the Accuracy of Clinical Diagnosis of Early Parkinson's Disease.
Mov Disord. 2023 Aug;38(8):1574-1575. doi: 10.1002/mds.29553.
5
Regional CBF changes in Parkinson's disease: the importance of functional neuroimaging analyses.
Eur J Nucl Med Mol Imaging. 2007 Sep;34(9):1455-7. doi: 10.1007/s00259-007-0411-8.
6
Accuracy of diagnosis in patients with presumed Parkinson's disease.
Age Ageing. 1999 Mar;28(2):99-102. doi: 10.1093/ageing/28.2.99.
7
Sudden death in Parkinson's disease: a retrospective autopsy study.
J Neurol Sci. 2014 Aug 15;343(1-2):149-52. doi: 10.1016/j.jns.2014.05.060. Epub 2014 Jun 2.
8
Clinical diagnosis of Parkinson's disease. Proposal of diagnostic subgroups classified at different levels of confidence.
Acta Neurol Scand. 1994 Apr;89(4):242-51. doi: 10.1111/j.1600-0404.1994.tb01674.x.
9
Clinical utility of visualisation of nigrosome-1 in patients with Parkinson's disease.
Eur Radiol. 2018 Feb;28(2):718-726. doi: 10.1007/s00330-017-4950-5. Epub 2017 Aug 4.
10
Estimating the Evolution of Disease in the Parkinson's Progression Markers Initiative.
Neurodegener Dis. 2018;18(4):173-190. doi: 10.1159/000488780. Epub 2018 Aug 8.
引用本文的文献
1
Machine Learning Approach to Select Small Compounds in Plasma as Predictors of Alzheimer's Disease.
Int J Mol Sci. 2025 Jul 21;26(14):6991. doi: 10.3390/ijms26146991.
2
Brain-derived extracellular vesicle microRNAs in Lewy body and Alzheimer's disease.
bioRxiv. 2025 Jun 9:2025.06.06.656900. doi: 10.1101/2025.06.06.656900.
3
Finger drawing on smartphone screens enables early Parkinson's disease detection through hybrid 1D-CNN and BiGRU deep learning architecture.
PLoS One. 2025 Jul 14;20(7):e0327733. doi: 10.1371/journal.pone.0327733. eCollection 2025.
4
The combination of the F-FDG PET and susceptibility-weighted imaging for diagnosis of cerebral glucose metabolism and iron deposition in Parkinson's disease.
Sci Rep. 2025 Jun 6;15(1):20029. doi: 10.1038/s41598-025-02672-x.
5
Brain-derived extracellular vesicles: A promising avenue for Parkinson's disease pathogenesis, diagnosis, and treatment.
Neural Regen Res. 2025 Apr 29. doi: 10.4103/NRR.NRR-D-24-01262.
6
Modernizing the Staging of Parkinson Disease Using Digital Health Technology.
J Med Internet Res. 2025 Apr 4;27:e63105. doi: 10.2196/63105.
7
Stability and Accuracy of a Diagnosis of Parkinson Disease Over 10 Years.
Neurology. 2025 May 13;104(9):e213499. doi: 10.1212/WNL.0000000000213499. Epub 2025 Apr 4.
8
Automated Imaging Differentiation for Parkinsonism.
JAMA Neurol. 2025 May 1;82(5):495-505. doi: 10.1001/jamaneurol.2025.0112.
9
Linguistic changes in spontaneous speech for detecting Parkinson's disease using large language models.
PLOS Digit Health. 2025 Feb 10;4(2):e0000757. doi: 10.1371/journal.pdig.0000757. eCollection 2025 Feb.
10
Refining α-synuclein seed amplification assays to distinguish Parkinson's disease from multiple system atrophy.
Transl Neurodegener. 2025 Feb 7;14(1):7. doi: 10.1186/s40035-025-00469-6.
本文引用的文献
1
Validation of the MDS clinical diagnostic criteria for Parkinson's disease.
Mov Disord. 2018 Oct;33(10):1601-1608. doi: 10.1002/mds.27362. Epub 2018 Aug 25.
2
Accuracy of clinical diagnosis of dementia with Lewy bodies: a systematic review and meta-analysis.
J Neurol Neurosurg Psychiatry. 2018 Apr;89(4):358-366. doi: 10.1136/jnnp-2017-316844. Epub 2017 Oct 13.
3
ACR-ACNM Practice Parameter for the Performance of Dopamine Transporter (DaT) Single Photon Emission Computed Tomography (SPECT) Imaging for Movement Disorders.
Clin Nucl Med. 2017 Nov;42(11):847-852. doi: 10.1097/RLU.0000000000001815.
4
Diagnostic utility of cerebrospinal fluid α-synuclein in Parkinson's disease: A systematic review and meta-analysis.
Mov Disord. 2017 Oct;32(10):1389-1400. doi: 10.1002/mds.27110. Epub 2017 Sep 7.
5
Amplified Detection of Prions and Other Amyloids by RT-QuIC in Diagnostics and the Evaluation of Therapeutics and Disinfectants.
Prog Mol Biol Transl Sci. 2017;150:375-388. doi: 10.1016/bs.pmbts.2017.06.003. Epub 2017 Jul 27.
6
Which ante mortem clinical features predict progressive supranuclear palsy pathology?
Mov Disord. 2017 Jul;32(7):995-1005. doi: 10.1002/mds.27034. Epub 2017 May 13.
7
Validation of the MDS research criteria for prodromal Parkinson's disease: Longitudinal assessment in a REM sleep behavior disorder (RBD) cohort.
Mov Disord. 2017 Jun;32(6):865-873. doi: 10.1002/mds.26989. Epub 2017 Apr 21.
8
The Systemic Synuclein Sampling Study: toward a biomarker for Parkinson's disease.
Biomark Med. 2017 Apr;11(4):359-368. doi: 10.2217/bmm-2016-0366. Epub 2017 Mar 29.
9
The Search for a Peripheral Biopsy Indicator of α-Synuclein Pathology for Parkinson Disease.
J Neuropathol Exp Neurol. 2017 Jan 1;76(1):2-15. doi: 10.1093/jnen/nlw103.
10
Incipient progressive supranuclear palsy is more common than expected and may comprise clinicopathological subtypes: a forensic autopsy series.
Acta Neuropathol. 2017 May;133(5):809-823. doi: 10.1007/s00401-016-1665-7. Epub 2017 Jan 7.
Zotero 插件